FIELD: chemistry; pharmaceutics.
SUBSTANCE: group of inventions relates to the chemical-pharmaceutical industry and is a liquid composition comprising a protein and a compound which prevents oxidation of protein in a liquid composition, selected from a group consisting of N-acetyl-L-tryptophanamide, 5-amino-DL-tryptophan, 5-hydroxyindole-3-acetic acid and melatonin, or a pharmaceutically acceptable salt thereof. Inventions also include a method for creating said protein composition and a method of preventing protein oxidation in said composition.
EFFECT: group of inventions enables to prevent oxidation of protein in a liquid composition without formation of active forms of oxygen during prolonged storage and treatment in the environment by using said compounds which are less light-sensitive and more prone to oxidation than L-tryptophan.
31 cl, 10 dwg, 7 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS WITH REDUCED OXIDATION | 2014 |
|
RU2707092C2 |
| METHODS FOR CELL CULTIVATION | 2018 |
|
RU2758674C2 |
| COMPOSITIONS AND METHODS, INCLUDING ALKYLGLYCOSIDES, FOR STABILISATION OF PROTEIN-CONTAINING COMPOSITIONS | 2011 |
|
RU2575830C2 |
| METHOD FOR OBTAINING BI-SPECIFIC ANTIBODIES, BI-SPECIFIC ANTIBODIES AND THERAPEUTIC APPLICATION OF SUCH ANTIBODIES | 2018 |
|
RU2795240C2 |
| ANTIBODIES TO BTN3A AND THEIR USE IN THE TREATMENT OF CANCER OR INFECTIOUS DISEASES | 2019 |
|
RU2800726C2 |
| ANTI-TFR ANTIBODIES AND USE THEREOF IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS | 2016 |
|
RU2737637C2 |
| ANTIBODIES TO CD40 FOR USE IN THE TREATMENT OF SJOGREN'S SYNDROME | 2018 |
|
RU2790558C2 |
| BINDING MOLECULES SPECIFIC FOR CD73, AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2730665C2 |
| ANTIBODY PURIFICATION METHODS | 2017 |
|
RU2759909C2 |
| MUTANT VARIANTS OF Fc IgG1 DEVOID OF EFFECTOR FUNCTIONS | 2018 |
|
RU2764559C2 |
